

**ADMERITOX** is a drug development consultancy, dedicated to providing high-quality support to the clients' preclinical projects regarding:

- development strategy,
- study monitoring,
- data assessment and presentation

**ADMERITOX** is owned by **Ria Vos PhD**



Ria has 20 years of experience in preclinical development of pharmaceuticals, comprising toxicology, ADME, and safety pharmacology. Her expertise ranges from the design of the program, to supervision, monitoring and reporting of the various studies, and the writing of the preclinical parts of regulatory documents such as the Common Technical Document. She has had the opportunity to contribute to meetings with the FDA and European regulatory agencies.

After a PhD in Toxicology and Biochemistry (Wageningen University, The Netherlands), Ria Vos joined the pharmaceutical company Organon in The Netherlands. She was manager of the ADME group, study director of ADME studies and a member of various Development Project Teams for 7 years. She then became manager of the preclinical International Project Team Representatives, where she supervised the preparation and implementation of development strategies (toxicology, ADME, safety pharmacology), safety evaluations prior to the start of "first in human" studies, and contributions to position papers and regulatory documents. After 5 years in that position, she moved to France for family reasons. She started ADMERITOX early 2004.


## SERVICES

**ADMERITOX** provides strategic and operational support in preclinical development of medicinal products, as well as support in the assessment of data and their presentation.

This support is reflected in the following services:

- analysis of / advice on development plans
- monitoring of toxicology, ADME and safety pharmacology studies
- scientific writing or review of
  - study reports
  - publications
  - position papers
  - preclinical parts of documents for regulatory submission

**ADMERITOX** has worked with international and multidisciplinary teams of various small and medium-sized pharmaceutical companies. Services provided since its start in 2004 are summarized in the figure below:



GA / NDP: gap analysis / nonclinical development plans

SA: strategic advice

BP: briefing package

SM: study monitoring

SR: study reports

IB / IMPD: Investigator's Brochure / Investigational Medicinal Product Dossier

CTD: Common Technical Document modules 2.6 and/or 2.4

SE: safety evaluations

RQ: regulatory questions

## **PRECLINICAL STRATEGY**

Toxicology, ADME, and safety pharmacology studies are essential for the development of a medicinal product and the submission of a marketing authorization application. For each drug project, a well-conceived preclinical development strategy, focussed on the clients' specific needs, is the indispensable basis of a first-time-right study program. A first-time-right approach results in the timely start of clinical development phases, efficient dossier preparation and an uneventful review by regulatory authorities.

By asking **ADMERITOX** to work out the preclinical strategy for a project, **YOU** as the client may expect:

- a preclinical strategy in compliance with the short-term and long-term project objectives and integrated with chemical, pharmaceutical, clinical and regulatory strategies
- a strategy tailored to existing data and the applicable regulatory guidelines
- clear rationales and objectives for the studies envisaged
- a development plan allowing to proceed to a satisfactory planning, an accurate budget and a successful control of the potential constraints

## PRECLINICAL STUDIES

A preclinical study – irrespective of whether it is conducted by the clients' organization or subcontracted – is an irrevocable building block of the dossier that will be submitted to regulatory authorities. Every study engaged under Good Laboratory Practices (GLP) and the generated data will need to be presented. It is therefore crucial to avoid ill-designed or ill-conducted studies as such studies will provide equivocal results and stretch development timelines.

A good study starts with a first-rate quality protocol. The subsequent experimental phase needs to be in line with this protocol. Finally, the report has to document the exact procedures followed, the results obtained and the conclusions drawn.

By asking **ADMERITOX** to take care of a study, **YOU** as the client may expect:

- a study protocol outline in line with the preclinical development strategy, the relevant existing data and the appropriate guidelines
- for studies to be subcontracted:
  - selection of the Contract Research Organization according to your prerequisites and standards
  - review of the study protocol
  - a "meeting zero" with the study team to exclude any misunderstanding of the contents of the study protocol
  - close monitoring of the critical study phases to ensure quality in terms of science and GLP and to keep you informed of the progress and the results
  - review of the study report
- for studies to be performed by your own organization:
  - any type of support required, e.g. coaching of the Study Director, quality control, review or scientific writing of the study protocol and/or report
- recommendations for amendment of the development plan in case of unexpected results that need further investigation

## **PRECLINICAL EVALUATION AND REGULATORY DOCUMENTS**

Entering a new clinical development phase or preparing an application for marketing authorization of a medicinal product requires a full and critical documentation of conducted studies and an integrated safety assessment of all available preclinical data. In addition, such an evaluation is important for the update of the development plan.

By asking **ADMERITOX** to prepare the preclinical parts of regulatory documents or to perform the integrated safety assessment of a product, **YOU** as the client may expect:

- an outline of the table of contents and the order of discussion of the conducted studies
- a well-structured and complete document, in compliance with your writing rules and regulatory format requirements (Common Technical Document) and with fully documented quality control
- a thorough and critical analysis of possible gaps in the study program and potential issues in the results
- recommendations on how to address the weak or missing elements by means of e.g. a literature search, a scientific position paper or an expert opinion
- additional evaluations of the interrelationships between preclinical and clinical or chemical/pharmaceutical data, if applicable and needed
- advice and assistance in the preparation of briefing packages for meetings with regulatory authorities

## BENEFITS

Preclinical development runs from the selection of a promising drug to regulatory submission of all generated data. Several, quite diverse disciplines are involved such as general toxicology, reproductive toxicology, pharmacokinetics, and metabolism. The long preclinical development life cycle may be associated with numerous unexpected events and results, that have to be recognized at an early stage and adequately dealt with.

By teaming up with **ADMERITOX**, **YOU** as the client may expect:

- focus on and first priority to your specific needs
- input based on extensive experience and expertise in ADME and safety testing, obtained in several therapeutic areas and for several routes of administration
- all-round support in every aspect of preclinical development, thus providing continuity all the way to preparation of the final dossier for a product
- tangible products: quality documents at a competitive price within pre-agreed timelines

## A COLLABORATION WITH A FOCUS ON YOUR BENEFIT



## **PRODUCTS AND THERAPEUTIC AREAS**

The experience in preclinical development of medicinal products is reflected in contributions to more than 100 projects, covering several types of products, therapeutic areas and routes of administration:

### **Types of products**

- chemical entities
  - new products
  - life cycle management
  - fixed combinations
- biological entities
  - monoclonal antibodies
  - recombinant proteins
- advanced therapy medicinal products
  - somatic cell therapy
  - tissue engineered products
- medical devices

### **Therapeutic areas**

- Alzheimer disease
- analgesia
- cardiovascular drugs incl. anti-thrombotic agents
- Central Nervous System-active drugs
- dermatology
- diabetes
- gastrointestinal diseases
- inborn errors of metabolism
- neuromuscular blocking agents
- oncology
- osteoarthritis (cartilage repair)
- reproductive medicine
- rheumatoid arthritis
- virology

### **Routes of administration**

- oral
- intravenous
- subcutaneous
- intramuscular
- inhalation
- intrathecal
- topical